<DOC>
	<DOCNO>NCT01416688</DOCNO>
	<brief_summary>RATIONALE : Questionnaires patient use assess skin toxicity relate treatment may help identify intermediate-and long-term effect cetuximab , panitumumab , erlotinib hydrochloride . PURPOSE : This trial study validation cancer questionnaire skin toxicity patient colorectal lung cancer receive cetuximab , panitumumab , erlotinib hydrochloride .</brief_summary>
	<brief_title>S1013 : Validation Cancer Questionnaire Skin Toxicities Patients With Colorectal Cancer Lung Cancer Receiving Cetuximab , Panitumumab , Erlotinib Hydrochloride</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish psychometric property Functional Assessment Cancer Therapy Epidermal Growth Factor Receptor Inhibitor ( FACT-EGFRI 18 ) module ( base criterion validity , know group 's validity , internal consistency reliability , responsiveness change ) patient-reported outcome ( PRO ) measure EGFRI-induced skin-related toxicity . Secondary - To document minimally important difference time FACT-EGFRI 18 compare mean change PRO measure patient 's direct assessment change use two anchor item ( change skin condition severity impact ) . - To examine association toxicity profile ( severity time onset ) , treatment profile ( e.g. , delay discontinuation ) FACT-EGFRI 18 score . - To assess degree concordance FACT-EGFRI 18 rating study site physician CTCAE Version 4.0 EGFRI-Induced Dermatologic Toxicity Grading Assessment rating . - To evaluate feasibility outcome . OUTLINE : This multicenter study . Patients complete S1013 Functional Assessment Cancer Therapy Epidermal Growth Factor Receptor Inhibitor ( FACT-EGFRI 18 ) baseline prior begin therapy clinical assessment . Patients also complete FACT-EGFRI 18 Changes Skin Symptoms day 1* , 8** , 15 , 22 , 29 , 36 , 43 , 71 , 99 , 127 . Patients develop grade papulopustular rash within 42 day remove study . Investigators perform patient ' clinical assessment complete EGFRI-Induced Dermatologic Toxicity Grading Assessment day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 71 , 99 , 127 , Treatment Form assessment day 22 , 43 , 71 , 99 , 127 . Nurses clinical trial administrator ( CRA ) also complete S1013 Cover Sheet Patient Complete Questionnaires accompany FACT-EGFRI 18 patient ' questionnaire schedule assessment . NOTE : *Patients start EGFRI therapy . NOTE : **Change Skin Symptoms questionnaire start Day 8 .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients must diagnosis colorectal lung cancer plan receive one follow epidermal growth factor receptor ( HER1/EGFR ) inhibitor therapy list least 6 week : Cetuximab 400 mg/m² load dose , 250 mg/m² weekly Cetuximab 500 mg/m² every 2 week Panitumumab 6 mg/kg every 2 week Erlotinib hydrochloride 100150 mg daily Other HER1/EGFR inhibitor therapy , schedule , dos list agent allow Concurrent chemotherapy anticancer therapy ( carboplatin , paclitaxel , bevacizumab ) allow EXCEPT follow chemotherapeutic agent know cause skin rash could interfere EGFRIinduced skin toxicity assessment : gemcitabine , capecitabine , topical fluorouracil ( Efudex™ , Fluoroplex™ , Carac™ ) Patients must complete baseline S1013 Functional Assessment Cancer Therapy ( FACT ) EGFRI 18 within 7 day prior registration PATIENT CHARACTERISTICS : Patients must Zubrod performance status 02 Patients must follow serious concomitant skin disorder , investigator 's opinion , could interfere assessment epidermal growth factor receptor inhibitor ( EGFRI ) induce skin toxicity : atopic dermatitis [ eczema ] ; contact dermatitis ; psoriasis ; rosacea ; severe photosensitivity ; scleroderma ; steroidinduced acne ; xerosis Patients must able complete questionnaire English PRIOR CONCURRENT THERAPY : See Disease Characteristics Patients may prior epidermal growth factor receptor ( HER1/EGFR ) inhibitor therapy must fully recover skin toxicity prior registration Patients must plan receive follow concomitant medication cause skin rash dermatologic reaction could interfere EGFRIinduced skin toxicity assessment , duration study : allopurinol ; systemic corticosteroid ; topical retinoids ( RetinA™ , Tretinoin™ ) ; oral retinoids ( Amnesteem™ , Claravis™ , Sotret™ ) Patients must plan receive concurrent externalbeam radiation therapy , include prophylactic cranial radiation Patients may concurrently participate therapeutic clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>therapy-related toxicity</keyword>
	<keyword>dermatologic complication</keyword>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage IIA colon cancer</keyword>
	<keyword>stage IIB colon cancer</keyword>
	<keyword>stage IIC colon cancer</keyword>
	<keyword>stage IIIA colon cancer</keyword>
	<keyword>stage IIIB colon cancer</keyword>
	<keyword>stage IIIC colon cancer</keyword>
	<keyword>stage IVA colon cancer</keyword>
	<keyword>stage IVB colon cancer</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage IIA rectal cancer</keyword>
	<keyword>stage IIB rectal cancer</keyword>
	<keyword>stage IIC rectal cancer</keyword>
	<keyword>stage IIIA rectal cancer</keyword>
	<keyword>stage IIIB rectal cancer</keyword>
	<keyword>stage IIIC rectal cancer</keyword>
	<keyword>stage IVA rectal cancer</keyword>
	<keyword>stage IVB rectal cancer</keyword>
	<keyword>stage IA non-small cell lung cancer</keyword>
	<keyword>stage IB non-small cell lung cancer</keyword>
	<keyword>stage IIA non-small cell lung cancer</keyword>
	<keyword>stage IIB non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>limited stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>